AbbVie’s Humira will now face lower-price competition from four new biosimilars: Boehringer Ingelheim’s Cyltezo, Celltrion’s Yuflyma, Organon and Samsung’s Hadlima, and Sandoz’s Hyrimoz.
AbbVie’s Humira will now face lower-price competition from four new biosimilars: Boehringer Ingelheim’s Cyltezo, Celltrion’s Yuflyma, Organon and Samsung’s Hadlima, and Sandoz’s Hyrimoz.